| Followers | 74 |
| Posts | 3928 |
| Boards Moderated | 0 |
| Alias Born | 03/23/2013 |
Friday, May 13, 2022 8:38:45 PM
Sabre,
Yes, I thought it was a buying opportunity for you if you were looking to lower your cost. Your strategy and outlook is completely different than mine.
Again, here's what I wrote:
I am a short term trader. Today I entered at the open and sold on the first intraday pullback for a +17% gain. I have not advocated holding AMRN; only trading, until certain conditions develop.
Is the low/bottom in? It could be, but has yet to confirm. ( it has to follow through).
All I can share with you is what I am doing and have done since FDA approval and that is buy deep reversals and sell after a pull up to falling resistance. Hopefully that changes one day and I can begin to buy at rising support and sell at resistance or hold long term. But my strategy/outlook is different than yours.
If you have confidence in the future of Amarin, then this is a smoking deal for the stock and it would be stupid to sell.
All the best,
ffs
You thought it was a buying opportunity back on the fourth but you sold today. Has something changed in the T/A that caused you to sell today at a lower price point than it was back on the fourth when you thought it was a buying opportunity? Should I be looking to cut my losses?
Yes, I thought it was a buying opportunity for you if you were looking to lower your cost. Your strategy and outlook is completely different than mine.
Again, here's what I wrote:
This is your opportunity to buy more. I believe we'll see a strong bounce after the open as shorts seize their chance to cover at a spike low.
This could be the red arrow I projected in the chart I shared a few days ago.
I am a short term trader. Today I entered at the open and sold on the first intraday pullback for a +17% gain. I have not advocated holding AMRN; only trading, until certain conditions develop.
Is the low/bottom in? It could be, but has yet to confirm. ( it has to follow through).
All I can share with you is what I am doing and have done since FDA approval and that is buy deep reversals and sell after a pull up to falling resistance. Hopefully that changes one day and I can begin to buy at rising support and sell at resistance or hold long term. But my strategy/outlook is different than yours.
If you have confidence in the future of Amarin, then this is a smoking deal for the stock and it would be stupid to sell.
All the best,
ffs
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
